All In Biotech

NDA 021919 · Amylin

Byetta

Exenatide Synthetic · Subcutaneous

Last checked: Nov 20, 2026Latest source record: Oct 30, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Oct 30, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

302

90 Phase 3, 8 recruiting

FAERS reports

52,320

14,635 serious, 1,764 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BYETTA · EXENATIDE SYNTHETIC 300UGM/1.2ML (250UGM/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • BYETTA · EXENATIDE SYNTHETIC 600UGM/2.4ML (250UGM/ML) · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Exenatide Synthetic" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased15,472
  • weight decreased12,126
  • nausea12,042
  • decreased appetite5,643
  • blood glucose decreased5,516
  • vomiting4,346
  • diarrhoea2,742
  • dizziness2,674
  • drug ineffective2,251
  • headache2,087
  • injection site pain2,023
  • pancreatitis2,011

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051,970
200612,666
200712,432
20087,681
20092,461
20101,753
20111,820
2012996
20131,460
20141,912
20152,516
20161,149
2017892
2018771
2019642
2020340
2021274
2022197
2023127
2024169
202575
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Byetta (Exenatide)

2024 spending

$15.9M

Beneficiaries

3,043

11,712 claims

Per beneficiary

$5,218

$459.82 per unit

View as table
YearSpending
2020$47,676,632
2021$37,988,662
2022$27,500,961
2023$20,645,626
2024$15,877,480

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Amylin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.